Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Liver Diseases
  • Lung Diseases
  • Phenylthiohydantoin
  • Prostatic Neoplasms, Castration-Resistant

abstract

  • Across multiple endpoints, patients who have visceral metastases have better outcomes with enzalutamide than with placebo. Cancer 2017;123:253-262. © 2016 American Cancer Society.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5632943

Digital Object Identifier (DOI)

  • 10.1002/cncr.30336

PubMed ID

  • 27648814

Additional Document Info

start page

  • 253

end page

  • 262

volume

  • 123

number

  • 2